AstraZeneca plans to invest $50B in its U.S. footprint by 2030. Some of that will be directed to a new GLP-1 manufacturing facility in Virginia.

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

New research from experts at the University of Virginia (UVA) says that GLP-1 drugs may help people lose weight, but do not ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...

Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side ...

The world of prior authorization, and the hoops we need to jump through, has gotten just more and more ridiculous, bordering ...

A WOMAN who lost a staggering five stone thanks to weight-loss jabs has hit back at trolls who brand her an “Ozempic cheat”.

With 700 challenger brands competing for attention, those offering functional benefits - particularly gut health - dominated the event as entrepreneurs raced to catch the eye of supermarket buyers and ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...